<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75953</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Impact of Preventive Treatment With Long-Acting B2-Adrenergic Agonists and Inhaled Corticosteroids on the Morbidity and Mortality of Severe Asthma Exacerbations in 1543 Patients</dc:title>
<dc:description xml:lang="en">Background and ObjectivesRecent systematic reviews and meta-analyses examining long-acting #b2-adrenergic agonists (LABA) as maintenance treatment for asthma have shown surprisingly conflicting results. The aim of the present study was to determine the impact, in terms of efficacy and safety, of previous maintenance treatment on severe asthma exacerbations.Patients and MethodsWe retrospectively evaluated the clinical characteristics of exacerbations experienced by 1543 patients with moderate persistent and severe persistent asthma. Drug therapy was as follows: a combination of inhaled LABAs and corticosteroids (493 patients), an inhaled corticosteroid only (456 patients), and no maintenance treatment (594 patients).ResultsAsthmatic patients taking LABAs did not show higher mortality, longer stay in the intensive care unit, longer hospital stay, lower pH, or worse airflow obstruction than the other 2 groups. On the contrary, they had a higher mean (SD) forced expiratory volume in 1 second at discharge (54% [16%]) than patients taking inhaled corticosteroids (48% [19%]) and patients taking no maintenance treatment (48% [20%]) (P=.009). Patients taking no maintenance treatment also had lower mean (SD) pH values (7.37 [0.11]) than patients taking LABAs (7.39 [0.09]) and patients taking inhaled corticosteroids (7.39 [0.08]) (P=.002), and more admissions to the intensive care unit (11.1% vs 6.5% and 7.7%; P=.002 and P=.018, respectively).ConclusionsThis study did not reveal higher morbidity or mortality in severe asthma exacerbations in patients with moderate persistent or severe persistent asthma who had received inhaled LABAs combined with inhaled corticosteroids. On the contrary, asthma patients who did not use maintenance treatment experienced more severe asthma exacerbations(AU)</dc:description>
<dc:creator>Neffen, Hugo</dc:creator>
<dc:creator>Bellido-Casado, Jesús</dc:creator>
<dc:creator>Sepúlveda, Ricardo</dc:creator>
<dc:creator>Plaza, Vicente</dc:creator>
<dc:creator>Rodríguez-Trigo, Gema</dc:creator>
<dc:creator>Rodrigo, Gustavo J</dc:creator>
<dc:creator>Perpi&amp;#241;á, Miguel</dc:creator>
<dc:creator>Solarte, Javier</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">ConclusionesEl presente estudio no constató una mayor morbimortalidad de la exacerbación asmática grave en los pacientes con asma persistente moderada-grave que recibían previamente tratamiento con un agonista adrenérgico &amp;#946;2 de acción larga y un glucocorticoide inhalados. Por el contrario, quienes no seguían tratamiento de mantenimiento presentaron una exacerbación más grave(AU)</dc:description>
<dc:source>Arch Bronconeumol;45(11): 545-549, nov. 2009. ilus, tab</dc:source>
<dc:identifier>ibc-75953</dc:identifier>
<dc:title xml:lang="es">Impacto del tratamiento preventivo con agonistas adrenérgicos B2 de acción larga y glucocorticoides inhalados en la morbimortalidad de 1.543 episodios de exacerbación grave de asma</dc:title>
<dc:subject>^d1257^s22080</dc:subject>
<dc:subject>^d28634</dc:subject>
<dc:subject>^d50295</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d325^s22020</dc:subject>
<dc:subject>^d325^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d325</dc:subject>
<dc:subject>^d325^s22073</dc:subject>
<dc:subject>^d6082^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d6082^s22000</dc:subject>
<dc:subject>^d1257^s22067</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d6082</dc:subject>
<dc:subject>^d1257^s22016</dc:subject>
<dc:subject>^d1257^s22027</dc:subject>
<dc:subject>^d1257^s22047</dc:subject>
<dc:type>article</dc:type>
<dc:date>200911</dc:date>
</metadata>
</record>
</ibecs-document>
